- Home
- VERU vs NXB Comparison
VERU vs NXB Comparison
Compare VERU & NXB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERU | NXB |
|---|---|---|
| Founded | 1971 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 49.2M |
| IPO Year | 1996 | 2025 |
Fundamental Metrics
Financial Performance| Metric | VERU | NXB |
|---|---|---|
| Price | $2.63 | $1.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 278.7K | 43.5K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $16,296,958.00 | ★ $119,866,298.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 21.08 |
| 52 Week Low | $2.05 | $1.79 |
| 52 Week High | $7.33 | $2.57 |
Technical Indicators
Market Signals| Indicator | VERU | NXB |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 44.44 |
| Support Level | $2.12 | $1.79 |
| Resistance Level | $2.67 | $2.32 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 65.75 | 36.91 |
Price Performance
Historical ComparisonAbout VERU Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
About NXB NextBoat Inc. Common Stcok
NextBoat Inc focused on AI-powered technology platform designed to modernize and scale the world-wide pre-owned marine marketplace.